Attention Deficit Hyperactivity Disorder Market Report 2026

The attention deficit hyperactivity disorder market size has grown strongly in recent years. It will grow from $17.38 billion in 2025 to $18.55 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to improved awareness of neurodevelopmental disorders, expanded diagnostic criteria across age groups, availability of stimulant medications, growth of behavioral therapy programs, increased recognition of adhd persistence into adulthood.

The attention deficit hyperactivity disorder market size is expected to see strong growth in the next few years. It will grow to $23.8 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing demand for long-acting medication formulations, rising focus on holistic mental health management, expansion of telepsychiatry services, growing investments in digital mental health platforms, increasing research into non-stimulant therapeutic options. Major trends in the forecast period include increasing adoption of non-stimulant medications, rising use of digital therapeutics and monitoring tools, growing focus on adult adhd diagnosis, expansion of personalized treatment approaches, enhanced integration of behavioral and pharmacological therapies.

The increasing adoption of personalized medicine is anticipated to drive the growth of the attention deficit hyperactivity disorder (ADHD) market in the coming years. Personalized medicine is a healthcare approach that customizes treatments based on an individual’s genetic, environmental, and lifestyle factors to achieve more precise and effective outcomes. This adoption is largely driven by advancements in genomic technologies, which allow treatments to be tailored according to a person’s genetic profile, resulting in more targeted and effective therapies. Attention deficit hyperactivity disorder (ADHD) plays a significant role in personalized medicine by enabling treatment strategies that account for an individual’s unique genetic, environmental, and behavioral traits, leading to more effective and focused interventions. For example, in February 2024, a report published by the Personalized Medicine Coalition (PMC), a US-based non-profit organization, highlighted that in 2023, personalized medicines represented over one-third of new FDA drug approvals for the fourth consecutive year. The FDA approved 16 new personalized treatments for rare diseases (up from 6 in 2022), 7 cancer drugs, and 3 treatments for other conditions. Consequently, the increasing adoption of personalized medicine is propelling the growth of the attention deficit hyperactivity disorder market.

Major companies in the ADHD market are concentrating on developing technological innovations such as video game-based digital therapeutics to offer non-pharmacological interventions, support attention management, and increase patient engagement. A video game-based digital therapeutic provides interactive, adaptive cognitive training through mobile devices, utilizing real-time performance tracking and closed-loop algorithms to enhance focus, attention control, and executive functioning compared with traditional stimulant or non-stimulant medications. For example, in June 2024, Akili Interactive, a US-based digital health company, introduced EndeavorOTC, the first FDA-cleared over-the-counter digital therapeutic for adult ADHD. The product employs Akili’s patented “Selective Stimulus Management Engine” to deliver multitasking and attention-challenging game tasks, automatically adjusting difficulty according to user performance. In a six-week pivotal study, 83% of participants demonstrated improved attentional control, and users reported increased productivity and quality of life.

In September 2024, Collegium Pharmaceutical Inc., a US-based specialty pharmaceutical company, acquired Ironshore Therapeutics Inc. for $525 million. The acquisition is intended to broaden its product portfolio beyond pain management and establish a presence in the expanding ADHD market with the differentiated product Jornay PM. Ironshore Therapeutics Inc. is a US-based company dedicated to developing and commercializing therapies for attention deficit hyperactivity disorder (ADHD).

Major companies operating in the attention deficit hyperactivity disorder market are Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Eli Lilly and Company, Johnson & Johnson, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc., Tris Pharma Inc., Mallinckrodt Pharmaceuticals plc, Arbor Pharmaceuticals LLC, KemPharm Inc., Cingulate Therapeutics LLC, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Rhodes Pharmaceuticals L.P., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Alkem Laboratories Ltd.

North America was the largest region in the attention deficit hyperactivity disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the attention deficit hyperactivity disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the attention deficit hyperactivity disorder market by increasing costs of imported active pharmaceutical ingredients, specialty excipients, packaging materials, and digital health hardware used in diagnosis and treatment delivery. Pharmaceutical suppliers in North America and Europe are most affected due to dependence on global API supply chains, while Asia-Pacific faces pricing pressure on generic medication exports. These tariffs are contributing to higher medication costs and slower rollout of new treatment options. However, they are also encouraging domestic drug manufacturing, regional API production, and investment in locally developed digital mental health solutions.

The attention deficit hyperactivity disorder market research report is one of a series of new reports that provides attention deficit hyperactivity disorder market statistics, including attention deficit hyperactivity disorder industry global market size, regional shares, competitors with a attention deficit hyperactivity disorder market share, detailed attention deficit hyperactivity disorder market segments, market trends and opportunities, and any further data you may need to thrive in the attention deficit hyperactivity disorder industry. This attention deficit hyperactivity disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder marked by ongoing inattention, hyperactivity, and impulsivity that disrupt daily functioning. It typically starts in childhood and can persist into adulthood, impacting concentration, self-regulation, and organizational skills. Management may involve behavioral therapy, medication, and modifications to lifestyle.

The primary treatments for attention deficit hyperactivity disorder (ADHD) consist of stimulants and non-stimulants. Stimulants are medications that increase brain activity to enhance focus, attention, and impulse control and are commonly used in managing ADHD. ADHD treatment is classified by age group into children and adults, and by gender into male and female. ADHD medications are available in different dosage forms, including tablets, capsules, and other forms, and are distributed through various channels such as retail pharmacies, hospital pharmacies, and online pharmacies.

The attention deficit hyperactivity disorder market consists of revenues earned by entities by providing services such as diagnosis, therapy, counselling, medication management, and digital health solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The attention deficit hyperactivity disorder (ADHD) market also includes sales of medical devices, digital therapeutics, and assistive learning tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.